Celltrion USA completes submission of Biologics License Application for CT-P47, a biosimilar candidate of ACTEMRA® (tocilizumab) ...Middle East

The Biologics License Application for CT-P47 was based on Phase III data comparing CT-P47 to the reference product ACTEMRA® (tocilizumab) JERSEY CITY, N.J., Jan. 28, 2024 /PRNewswire/ -- Celltrion USA today announced the submission of Biologics License Application (BLA) to the U.S. Food...

Hence then, the article about celltrion usa completes submission of biologics license application for ct p47 a biosimilar candidate of actemra tocilizumab was published today ( Monday 29/01/2024 - 02:32 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Celltrion USA completes submission of Biologics License Application for CT-P47, a biosimilar candidate of ACTEMRA® (tocilizumab) )

Also on site :

• Bank of England must plan for a financial crisis triggered by Aliens, says former policy expert
• Finn Wolfhard's 'Stranger Things' SNL Skit Met With Backlash From Fans
• Former UK police officer stripped of citizenship after moving to Russia